Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial

Chao Deng,Qing Liu,Meng Yang,Hui-juan Cui,Yang Ge,Qin Li,Shi-jie Zhu,Guo-wang Yang,Zhi-guo Zhang,Yu Gao,Yan-ni Lou,Li-qun Jia
DOI: https://doi.org/10.1186/s13020-024-01025-6
IF: 4.546
2024-11-07
Chinese Medicine
Abstract:Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We designed this clinical trial to supply more evidences on the use of SXD as prophylaxis for irinotecan-induced diarrhea, especially for high-risk population predicted by gene testing of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1).
pharmacology & pharmacy,integrative & complementary medicine
What problem does this paper attempt to address?